Next Post

$500m CartiHeal sale to go ahead after FDA approval granted

&#13 US orthologics business Bioventus (Nasdaq: BVS) can now continue with its $500 million acquisition of CartiHeal, immediately after the Israeli clinical device corporation acquired Food and drug administration clearance for its implants for the procedure of ruined cartilage. Bioventus signed an arrangement to purchase CartiHeal previous July, for $350 […]